Overview
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.
Eligibility
Inclusion Criteria:
- </= 28 years of age
- Performance status >/= 40
- DLCO >/= 40%
- LVEF >/=40% or LVSF >/=26%
- Serum creatinine < 2x ULN
- Liver enzymes </= 5x ULN
- Negative pregnancy test
- Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 5-6/6 matched unrelated UCB, 7-8/8 matched unrelated BM, double cord)
Exclusion Criteria:
- Known diagnosis of HIV I/II
- Pregnant or breastfeeding
- Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting alemtuzumab
- Uncontrolled viral infection within 1 week prior to starting alemtuzumab